Big news for bimekizumab in plaque psoriasis

17 October 2019

Shares in Belgian drugmaker UCB (Euronext: UCB) were buoyed by positive Phase III data for the firm’s key pipeline candidate, bimekizumab, on Thursday.

UCB stock was trading about 5% higher by mid-afternoon, after the firm announced that the BE VIVID study, which is evaluating the interleukin (IL)-17A and IL-17-F inhibitor in adults with moderate-to-severe plaque psoriasis, met its co-primary endpoints.

Bimekizumab is an important candidate for the future of the company, which is looking to grow beyond the success of the blockbuster Cimzia (certolizumab pegol) in immunology. Patents on the product will expire in Europe in 2021 and in the USA in 2024.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK